InSite Vision is committed to developing new technologies and advanced products that will improve eye health and vision. With a highly experienced team and focused operations in specialty ophthalmic product development, we seek strategic alliances and mutually beneficial collaborations to advance this objective.
Commercial partnerships: InSite Vision receives royalty payments from our two commercial products, AzaSite® (azithromycin ophthalmic solution) 1% and Besivance™ (besifloxacin ophthalmic suspension) 0.6%. AzaSite is approved in the United States and Canada and marketed by InSite Vision’s partner, Inspire Pharmaceuticals, a wholly owned subsidiary of Merck & Co. (NYSE:MRK). InSite Vision has also formed multiple strategic licensing and distribution agreements with partners to market AzaSite in select countries in Europe, Asia and South America upon regulatory approval in those regions. Besivance was approved by the U.S. Food and Drug Administration in 2009 and is being commercialized by Bausch & Lomb and Pfizer Inc. We work closely with our partners to support and extend product sales.
Development Partnerships: We seek to collaborate with other companies who share our vision of creating unique therapeutic products of lasting value. InSite Vision has advanced a number of internal product candidates while retaining the option to work with development partners to complete the clinical development and/or commercialization of a given product opportunity.
In addition, our DuraSite technology platform offers significant therapeutic advantages in new product development for new ocular product candidates using either non-proprietary drugs or compounds developed by others for non-ophthalmic indications. InSite is seeking partnerships focused on advancing new product candidates that leverage DuraSite to address unmet needs in eye pain, inflammation and/or infection.
In-licensing and acquisition opportunities: We are actively reviewing promising new late-stage products and technologies for potential in-licensing or acquisition. Upon obtaining the rights to new products, we will apply our product development and technology expertise to advance novel differentiated ophthalmic products.
- For more information about partnering and licensing opportunities with InSite Vision, Click here.
- AzaSite® is the registered trademark owned by InSite Vision, Inc. and is licensed Inspire Pharmaceuticals, a wholly owned subsidiary of Merck & Co. (NYSE:MRK)
- For information regarding the sale or use of AzaSite® in the United States and Canada Click here or call (888) 881-4696.
- For full prescribing information for AzaSite Click here.